Psycheceutical Bioscience, Inc BWVI is a biotechnology company with patented technology that says it aims to revolutionize the psychedelic mental health space and disrupt Big Pharma. The company is ...
Phase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketamine Phase II trial will study 115 participants with PTSD and look at the ...
Investors are invited to support Psycheceutical's mission to revolutionize psychedelic medicines by taking part in the company's Wefunder Community Round. MIAMI, FL / ACCESSWIRE / November 1, 2023 ...
Psycheceutical recently announced the approval of two of its patents that could revolutionize psychedelic medicine delivery systems. The technologies allow psychedelic drugs to bypass the stomach, ...
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the ...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical cream ...
Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects FT. LAUDERDALE, FL / ACCESSWIRE / April 18, ...
Publicly traded psychedelics company Psycheceutical Bioscience Inc. BWVI is signing an exclusive purchase option with end-to-end pharma R&D company Vici Health Sciences’ majority equity stake. The ...
Psycheceutical's NeuroDirect™ ketamine technology is the first ketamine topical being developed to treat PTSD Clinical trial program now underway, with first cohort dosing showing the ketamine topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback